Keystone to Secure Safety After Stopping Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B Patients.
作者信息
Liu Yen-Chun, Jeng Wen-Juei, Chen Chien-Hung
机构信息
Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan City; College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
Department of Gastroenterology and Hepatology, Kaohsiung Chang Gung Memorial Hospital, Taoyuan City; College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
出版信息
Clin Gastroenterol Hepatol. 2022 Aug;20(8):1890-1891. doi: 10.1016/j.cgh.2021.09.030. Epub 2021 Sep 25.
PMID:34583016
Abstract
摘要
相似文献
1
Keystone to Secure Safety After Stopping Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B Patients.慢性乙型肝炎患者停止核苷（酸）类似物治疗后确保安全的关键。
Clin Gastroenterol Hepatol. 2022 Aug;20(8):1890-1891. doi: 10.1016/j.cgh.2021.09.030. Epub 2021 Sep 25.
2
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.聚乙二醇干扰素 α-2a 联合核苷（酸）类似物治疗与单独核苷（酸）类似物治疗对 HBeAg 阴性慢性乙型肝炎患者持续不可检测的血浆乙型肝炎病毒 DNA 的影响：一项随机、对照、开放标签试验。
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):177-188. doi: 10.1016/S2468-1253(16)30189-3. Epub 2017 Jan 20.
3
Anti-HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B.抗-HBc水平预测慢性乙型肝炎患者停用核苷（酸）类似物后的病毒学复发
Liver Int. 2023 Apr;43(4):947-948. doi: 10.1111/liv.15536. Epub 2023 Feb 17.
4
Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.停止 HBeAg 阴性慢性乙型肝炎核苷（酸）类似物治疗后乙型肝炎病毒特异性 T 细胞应答。
J Hepatol. 2018 Sep;69(3):584-593. doi: 10.1016/j.jhep.2018.05.004. Epub 2018 Jun 29.
5
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.JNJ-73763989 与 JNJ-56136379（贝沙卡韦）联合核苷（酸）类似物治疗慢性乙型肝炎病毒感染的疗效和安全性（REEF-1）：一项多中心、双盲、活性对照、随机、2b 期临床试验。
Lancet Gastroenterol Hepatol. 2023 Sep;8(9):790-802. doi: 10.1016/S2468-1253(23)00148-6. Epub 2023 Jul 10.
6
Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.对于 HBeAg 阴性慢性乙型肝炎的部分患者，停止长期核苷（酸）类似物治疗是一个有利的选择。
Liver Int. 2018 Feb;38 Suppl 1:90-96. doi: 10.1111/liv.13654.
7
Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.核苷（酸）类似物仅能使大多数慢性乙型肝炎患者的乙型肝炎 e 抗原血清学转换暂时发生。
Gastroenterology. 2010 Aug;139(2):491-8. doi: 10.1053/j.gastro.2010.03.059. Epub 2010 Apr 8.
8
Severe Acute Exacerbation After Cessation of Nucleos(t)ide Analog for Chronic Hepatitis B: A Real-World Study of Routine Practice.慢性乙型肝炎核苷（酸）类似物停药后严重急性加重：一项常规实践的真实世界研究
Clin Gastroenterol Hepatol. 2022 Jun;20(6):1413-1415.e3. doi: 10.1016/j.cgh.2021.08.037. Epub 2021 Aug 28.
9
A comment on "A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B".关于“一项关于HBeAg阴性慢性乙型肝炎核苷（酸）类似物停药的多中心随机对照试验”的评论
J Hepatol. 2024 May;80(5):e229-e230. doi: 10.1016/j.jhep.2023.07.038. Epub 2023 Aug 11.
10
Reply to: "A comment on `A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B'".回复：“对‘一项关于HBeAg阴性慢性乙型肝炎核苷（酸）类似物停药的多中心随机对照试验’的评论”
J Hepatol. 2024 May;80(5):e230-e231. doi: 10.1016/j.jhep.2023.11.034. Epub 2023 Dec 16.
Zotero 插件